重和林M30在新诊2型糖尿病中的应用

目的：观察重和林M 30（精蛋白重组人胰岛素30／70）在新诊2型糖尿病人中的临床作用。方法选取80例需胰岛素治疗的2型糖尿病人，随机分为重和林M 30组（试验组）与门冬胰岛素30组（对照组），连续治疗8周，比较两组治疗前后空腹血糖（FBG）、餐后2 h血糖（PBG）、体重指数（BMI）、糖化血红蛋白（HbA1c）、空腹C肽（Fasting C peptide ，FCP）变化，评估低血糖、严重低血糖发生率及胰岛素用量和性价比。结果两组患者FBG、PBG、HbA1c、FCP较治疗前均有明显下降（P＜0.05），两组患者治疗后的FBG、BMI、HbA1c、FCP比较无明显差异（P＞0.05）；两组患者低血糖发生率及胰岛素用量无明显差异（ P＞0.05 ），两组治疗后均未见严重的低血糖反应，试验组性价比较高。结论重和林M 30与门冬胰岛素30治疗新诊2型糖尿病整体降糖疗效无明显差异，重和林M 30性价比较高，在基层医院具有广泛应用优势。

The application of SciLin M30 in patients with newly diagnosed type 2 Diabetes

Objective To observe the effect of SciLin M30（Isophane Protamine Recombinant Human Insulin M30）on newly diagnosed type 2 diabetes .Methods Eighty newly diagnosed hospitalized patients with type 2 diabetes were selected .Eighty ca‐ses were randomly divided into two groups with one group treated by BIASP30 and the other by SciLin M30 .An open and ran‐dom study was performed for eight weeks .FBG ,PBG ,BMI ,FCP and HbA1c were measured before and after treatment .Inci‐dences of hypoglycemia and severe hypoglycemia ,dosages of insulin and cost performance were compared .Results FBG ,BMI , HbA1C FCP levels of patients in SciLin M 30 and BIASP30 groups were significantly lower than those before treatment （P〈0 . 05） .There were no significant differences in the levels of FBG ,BMI ,HbA1c ,FCP after treatment between two groups （P〉0.05） .The incidence of hypoglycemia and the dosage of insulin were not significantly different between two groups （P〉0.05） . No severe hypoglycemia happened in two groups .The cost performance of SciLin M30 group was higher than that of BIASP30 group .Conclusion There was no significant difference between SciLin M 30 and BIASP30 in the control of blood glucose .SciLin M30 was cheaper than BIASP30 ,so it had some superiority in basic hospitals .